WORKSHOP ON INTEGRATING INFECTIOUS DISEASE CONSIDERATIONS WITH RESPONSE TO THE OPIOID EPIDEMIC

Policy and Research Priorities to Reduce Infectious Diseases Associated with Opioid Use Disorder
March 13, 2018
William Powderly, MD, FIDSA
Immediate-Past President, IDSA
Dr. J. William Campbell Professor of Medicine and the Larry J. Shapiro Director of the Institute for Public Health, Washington University in St. Louis
Who We Are

• IDSA represents more than 11,000 physicians, scientists and other health care professionals who specialize in infectious diseases.

• Our purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.

• Created the HIV Medicine Association to represent the diversity of HIV health care providers and promote quality HIV care by advocating for policies that ensure a comprehensive and humane response to the AIDS pandemic.
Relevant Activities

• Partner with AASLD to maintain HCVGuidance.org

• Published guideline on chronic pain management in HIV patients (Oct 2017)

• Advocate for federal funding for ID and HIV prevention, care & treatment and research

• Advocate for evidenced-based prevention including syringe services programs & safe-consumption sites

• Provide clinical updates on managing opioid-related infections at IDWeek
Top Responses:
- Infective endocarditis (many report a doubling or more)
- Acute HCV cases
- Osteomyelitis
- Skin abscesses
- HIV

It's far more than overdoses: IV opioid users' diseases overwhelm hospitals

Jayne O'Donnell and Terry DeMio, USA TODAY Network
Published 10:00 a.m. ET Nov. 8, 2017 | Updated 8:06 a.m. ET Nov. 15, 2017
Top Responses:

• Syringe exchange
• Safe injection areas and education on safe injection practices
• Increased access to medication for addiction treatment and integration of MAT into primary care & specialty care
• More supportive inpatient facilities to treat endocarditis and addiction

By Todd Huffman from Phoenix, AZ – Needle Exchange, CC BY 2.0
<table>
<thead>
<tr>
<th>Key policy issues identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heightened prevention</td>
</tr>
<tr>
<td>Need more epidemiological data and enhanced surveillance</td>
</tr>
<tr>
<td>Build health care provider capacity through telehealth &amp; provider training</td>
</tr>
<tr>
<td>Expanded access to HIV, HCV and other ID treatment and to addiction treatment</td>
</tr>
<tr>
<td>Research and support for models to co-treat addiction and infections</td>
</tr>
</tbody>
</table>
HEIGHTENED PREVENTION

Invest new resources in the CDC to:

- Build state and local health department capacity to respond to their local opioid epidemic
- Expand access to syringe services programs
- Support jurisdictions implementing safe consumption sites
- Fully implement national HIV, hepatitis B, and hepatitis C screening guidelines
Enhanced Surveillance & Data

• Increase funding to expand surveillance for hepatitis C

• Generate and track national epidemiologic data including morbidity and mortality on infective endocarditis and other infections associated with opioid use
• Leverage telehealth to expand access to ID and addiction treatment
• Increase funding at SAMHA & HRSA for addiction training for clinicians – including ID specialists – on the frontlines of the opioid epidemic
• Support frontline clinicians prescribing medication for addiction treatment with resources such as case managers and on site counselors
• Attract Addiction & ID/HIV specialists to underserved areas by expanding loan forgiveness opportunities
EXPANDED ACCESS TO ADDICTION TREATMENT AND TREATMENT FOR HIV, HCV AND OTHER INFECTIOUS DISEASES

• Expand access to substance & mental health treatment including Medication for Addiction Treatment

• Fully leverage HRSA’s Ryan White HIV/AIDS Program to improve access to prevention & treatment for people with HIV with opioid use disorder

• Address barriers to HCV treatment including coverage restrictions such as requiring sobriety and limiting the types of providers who can prescribe HCV treatment
IMPROVE CARE INTEGRATION & LINKAGES

• Inpatient & outpatient clinics

• Jails, prisons & community providers

• Addiction specialists, psychiatrists, primary care clinicians, surgeons & infectious diseases physicians
ADDRESS RESEARCH GAPS IN SERVICE DELIVERY, HARM REDUCTION & TREATMENT

• Need effective models for co-treating & integrating addiction & infectious diseases treatment, e.g., treating endocarditis & addiction

• Study long-acting glycopeptides in treatment of endocarditis

• Need to know more about how to effectively implement evidence-based interventions, patient care including Pre-Exposure Prophylaxis (PrEP) & safe consumption sites
Prioritize Research on Vulnerable Populations

Justice-involved individuals and rural populations are disproportionately affected and face unique prevention & treatment challenges.
Committed to Provider & Policymaker Education and Advocacy

Upcoming Resources

• Fact sheet on ID and OUD
• Policy brief and recommendations
• Letter to NIH on key research questions

Next Steps

• Outreach to Congress and Administration
• Advocacy for policies and funding to address ID and OUD
• Media and social media

Staff Contacts:
Amanda Jezek
Sr. Vice President
IDSA Public Policy & Government Relations
ajezek@idsociety.org
www.idsociey.org

Andrea Weddle
Executive Director
HIVMA
aweddle@hivma.org
www.hivma.org
@hivma.org

@idsainfo